SCF, a glycoprotein growth factor, is the ligand for the tyrosine kinase receptor encoded by c-kit (1). In the presence of other hematopoietic growth factors, but not when used singly, SCF supports clonogenic maturation of hematopoietic progenitors obtained from the marrow of adult subjects (1-4). Murine studies indicate that SCF is expressed during the embryonic period and that, unlike GM-CSF and IL-3, SCF might play a role in early fetal hematopoietic differentiation and development (5, 6). The effect of SCF on human fetal hematopoietic progenitors, however, has not been reported. We hypothesized that SCF, in a manner similar to the cytokines IL-6 (7), IL-9 (8), and IL-I 1 (9), might have a broader spectrum of action on fetal than on adult hematopoietic progenitors. Specifically, we sought to determine whether SCF as a single agent might induce clonogenic maturation of fetal progenitors and whether it would act synergistically with other factors, such as IL-3 and GM-CSF.
MATERIALS AND METHODS
Sltbjects. Fetal blood was obtained by puncture of the umbilical vein at the placental end of the umbilical cord immediately after elective term cesarean section deliveries without labor. The studies were performed in accordance with protocols approved by the University of Utah Institutional Review Board.
Recombinant hematopoietic g r o~h factors. Purified recombinant IL-3, G-CSF, and GM-CSF (R&D Systems, Minneapolis, MN) were produced in Escherichia coli and purified to homogeneity, 95% or greater purity as determined by SDS-PAGE. Purified recombinant human erythropoietin (provided by Chugai-Upjohn Inc., Rosemont, IL) had a specific activity of more than 3 x lo5 IU/mg with a purity of more than 99.7% by SDS-PAGE. SCF (provided by Krisztina Zsebo, Amgen Inc., Thousand Oaks, CA) was produced by COS-I cells transfected with SCF cDNA as previously described (3) .
Antihuman IL-3 and antihuman GM-CSF antibodies were raised in goats immunized with purified recombinant human IL-3 and GM-CSF (R&D Systems). At a concentration of 10 mg/ L, anti-IL-3 neutralized approximately 80% of the biologic activity of 1.25 pg/L of recombinant human IL-3, but did not cross-react with IL-I, IL-2, IL-4, IL-6, tumor necrosis factor, GM-CSF, or G-CSF as determined by Western blot or ELISA. Anti-GM-CSF neutralized more than 90% of the biologic activity of 0.5 pg/L of recombinant human GM-CSF. No crossreactivity with IL-I, IL-2, IL-3, IL-4, IL-6, tumor necrosis factor, or G-CSF was detected by Western blot or ELISA.
Clonogenic cultzires. Light-density cells (sp gr < 1.077) obtained from umbilical cord blood by density gradient centrifugation over Ficoll-Hypaque were incubated for 90 min in plastic flasks at 37"C, after which nonadherent cells were incubated for 20 min at room temperature with murine antihuman monocyte (Leu-MS, Becton Dickinson, Mountain View, CA), anti-T lym- Tritiated fhytnidine szticide stlrdies. Fetal light-density cells were incubated at 37°C and 5% COz, under serum-free conditions, for 3.5 h in either a-MEM alone or in n-MEM with SCF (0.5, 5, or 50 jig/L). Tritiated thymidine suicide studies were then performed according to the methods of Lu et a/. (10) . Briefly, after the incubations, each aliquot was split into three tubes. Tritiated thymidine of high specific activity (86 Ci/mmol, Amersham, Arlington Heights, IL) was added to one tube, nontritiated cold thymidine (500 pg, Sigma) was added to a second tube, and tritiated thymidine plus cold thymidine was added to a third tube for an additional 20-min incubation, with agitation every 5 min. Cells were then washed twice with cold thymidine wash buffer (100 mg/L) and plated in clonogenic cultures in the presence of IL-3 ( 1 pg/L), GM-CSF ( I pg/L), and G-CSF ( 1 pg/ L). Erythropoietin (2000 IU/L) was added to all cultures after 72 h.
Data analysis. Statistical comparisons were performed using the two-tailed t test.
RESULTS
The effect of SCF on clonogenic maturation of fetal CFU-GM is shown in Table 1 . As a single agent, SCF ( 2 5 pg/L) supported development of fetal CFU-GM colonies (5 k 1 CFU-GM colonies/104 plated cells in control plates versus 17 + 2 colonies in plates to which SCF was added; p < 0.05). The effect of SCF on CFU-GM formation was additive to that of a subplateau concentration (0.1 jig/L) of IL-3. SCF (5 pg/L) was also additive to a subplateau (0.1 pg/L) as well as a higher concentration (5.0 pg/ L) of GM-CSF and to the combination of IL-3 plus GM-CSF The effect of SCF on clonogenic maturation of fetal BFU-E is shown in Table 3 . As a single agent, SCF ( 2 5 pg/L) supported development of fetal BFU-E; however, no additive effect on the number of BFU-E colonies formed was observed when SCF was added to IL-3, GM-CSF, or to combinations of IL-3 plus GM-CSF. Despite the lack of increase in BFU-E colony number, the size of the individual BFU-E colonies increased when grown in the presence of SCF (Fig. 1) .
Incubation of fetal progenitors for 4 h with SCF in concentrations of 0.5 to 50 pg/L did not result in a n increase in the proportion of progenitors killed by tritiated thymidine of high specific activity. Thus, the proliferative action of SCF on fetal progenitors does not appear to be the result of the direct action of SCF on cell cycle status of hematopoietic progenitors. DISCUSSION SCF appears to have a critical role in embryonic and fctal hematopoietic development. Schmitt et al. (5) observed that SCF and c-kit were among the factors expressed in undifferentiated embryonic murine stem cells, whereas GM-CSF and IL-3 were not. The importance of SCF and its interaction with the c-kit receptor during early development are illustrated by murine strains with mutations at the W locus encoding the c-kit product and mice with the mutation of the S 1 locus encoding SCF protein (1, 1 1-13 ). Both strains exhibit pleotropic developmental defects not only in hematopoiesis but also in gametogenesis and melanogenesis (6, 1 1 -13).
The precise role of SCF in human fetal hematopoietic development is not clear. The present studies indicate that progenitors of human fetal origin can be influenced by recombinant SCF and that, in a manner similar to IL-6, IL-9, and IL-I I, SCF has a somewhat broader spectrum of action on fetal progenitors than that reported by other investigators on adult hematopoietic progenitors because adult progenitors d o not develop clones when stimulated by SCF alone (7-9). Specifically, we observed that when used as a single agent, SCF supported clonogenic maturation of about 70% of the CFU-GM colonies that developed when stimulated with IL-3 and about 60% of the CFU-GM colonies that developed when stimulated with GM-CSF. This effect appears to be independent of in vitro expression of IL-3 and GM-CSF by fetal progenitors in culture because neutralizing antibodies to IL-3 and GM-CSF were included in the culture media (14) .
.CSF on the number of normoblasts per B N -E colony. B N -E from three i were counted on a hemocytometer. The numbers represent mean + SEM.
SCF exhibited synergistic effects with IL-3 and GM-CSF, resulting in not only an increase in the number of colonies but also in the quantity of cells per colony.
At the highest dose of SCF (50 pg/L) evaluated, a loss of synergism was observed with either IL-3 or GM-CSF with respect to maturation of CFU-GM and CFU-MIX colonies. One possible explanation for this phenomenon is that high SCF concentrations down-regulate its receptor, c-kit. This effect of high concentrations of SCF has been documented by two groups of investigators (6, 15) . A second explanation is that with high ligand (SCF) concentration the efficiency of dimerization of c-kit receptor is diminished (6). Yet another possibility is that large quantities of soluble SCF might inhibit cell-cell interactions mediated through the membrane-bound form of SCF on one cell interacting with the receptor on an adjacent cell in culture (16, 17) . This interaction, which appears to be important in maintenance of hematopoietic stem cells in long-term culture, might be inhibited by binding of excess soluble SCF to receptors or by downregulation of SCF receptors on adjacent cells.
Although the regulation of hematopoiesis during fetal development is poorly understood, this area of study is becoming relevant to clinicians as well as to scientists. An understanding of fetal hematopoietic control provides insight into the pathophysiologic mechanisms operative in prematurely delivered neonates. For instance, a n important problem in neonatology practice involves the very high incidence of nosocomial infections in extremely preterm infants (18) . The basis for this defective antibacterial defense appears to involve a relatively small neutrophil reserve per kilogram of body weight (19, 20) , a significant limitation in up-regulating neutrophil production during bacterial infection (2 I), and relatively poor neutrophil adherence, chemotaxis, and superoxide generation (22) (23) (24) (25) (26) (27) . Effective and safe methods of improving neutrophil production and function in preterm neonates would be of interest as potential means of decreasing the incidence or severity of infections. With this in mind, Cairo ct a/. (28, 29) tested the administration of various hematopoietic growth factors and cytokines, alone and in combination, to newborn rats. Promising results from the combination of G-CSF and SCF included a significant increase in blood and marrow neutrophil populations, improved neutrophil function, and improved survival after bacterial challenge (29) . On the basis of the animal studies and the present experiments with human cells, we suspect that SCF is an important hematopoietic regulator in the human fetus. Issues regarding its regulation and actions, and any potential as a therapeutic agent in perinatal medicine, remain to be determined.
